Cipla forms alliance with Serum Institute to market paediatric vaccines in Europe

Adar Poonawalla

Venturing into the vaccines segment, Cipla, through its subsidiary Cipla Europe NV, has entered into an agreement to distribute Serum Institute of India Ltd’s (SII) paediatric vaccines in Europe. As per the agreement, Serum Institute of India, a Poonawalla group company and one of the leading manufacturers of vaccines in India, will develop and manufacture paediatric vaccines, while Cipla will seek European Medicines Agency approval and market the products in Europe. The vaccines will be manufactured in Serum’s production facilities approved by WHO.
 
Subhanu Saxena, MD & Global CEO, Cipla Limited, said, “We are proud to have entered into a strategic Europe-specific partnership with Serum Institute of India. This collaboration is aligned with our commitment to access to affordable paediatric healthcare. Both Cipla and SII share the same core values such as self-sufficiency, affordability, accessibility, quality and commitment to global health. Through this partnership, we look forward to contribute in eradication of childhood diseases.”
 
Adar Poonawalla, CEO and Executive Director, SII, added, “Serum Institute believes that this tie-up with Cipla is a perfect platform for making vaccines available for Europeans as Serum also shares the common philosophy of Cipla of making vaccines/pharmaceutical products available at the most affordable prices. Therefore as the two companies are aligned in many ways, we feel this will be a good partnership.”
 
According to Frank Pieters, Head of Europe, Cipla, the company sees vaccines as one of the critical components of its offering to European patients. “With Cipla’s front-end presence and with the support of a dedicated sales force, we will broaden the reach of vaccines across Europe,” he added.
 
Over the last 6 months, Cipla has strengthened its foundation in Europe. The company has launched respiratory products such as Salmeterol/Fluticasone in Germany and Sweden, Czech Republic, Slovakia and Croatia. In July, Cipla has signed an exclusive partnership with BioQuiddity to market OneDoseReadyfusORTM in regional anesthetic applications for post-surgical pain management.

Source: Business Standard